[go: up one dir, main page]

WO2016005564A3 - Anticorps dirigés contre le facteur v activé - Google Patents

Anticorps dirigés contre le facteur v activé Download PDF

Info

Publication number
WO2016005564A3
WO2016005564A3 PCT/EP2015/065848 EP2015065848W WO2016005564A3 WO 2016005564 A3 WO2016005564 A3 WO 2016005564A3 EP 2015065848 W EP2015065848 W EP 2015065848W WO 2016005564 A3 WO2016005564 A3 WO 2016005564A3
Authority
WO
WIPO (PCT)
Prior art keywords
activated factor
antibodies against
against activated
factor
fva
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2015/065848
Other languages
English (en)
Other versions
WO2016005564A2 (fr
Inventor
Heidi Lindgreen Holmberg
Gustav RØDER
Kristoffer Winther BALLING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of WO2016005564A2 publication Critical patent/WO2016005564A2/fr
Publication of WO2016005564A3 publication Critical patent/WO2016005564A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux ou des fragments de ceux-ci, qui se lient au Facteur V activé (FVa), qu présentent un effet pro-coagulant, ainsi que leurs utilisations thérapeutiques.
PCT/EP2015/065848 2014-07-11 2015-07-10 Anticorps dirigés contre le facteur v activé Ceased WO2016005564A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14176717 2014-07-11
EP14176717.8 2014-07-11

Publications (2)

Publication Number Publication Date
WO2016005564A2 WO2016005564A2 (fr) 2016-01-14
WO2016005564A3 true WO2016005564A3 (fr) 2016-04-07

Family

ID=51162604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/065848 Ceased WO2016005564A2 (fr) 2014-07-11 2015-07-10 Anticorps dirigés contre le facteur v activé

Country Status (3)

Country Link
AR (1) AR101185A1 (fr)
TW (1) TW201617371A (fr)
WO (1) WO2016005564A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3077084A1 (fr) 2017-10-05 2019-04-11 Epivax, Inc. Epitopes de lymphocytes t regulateurs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910576A (en) * 1994-02-14 1999-06-08 Rijks Universiteit Leiden Method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein
WO2005111075A2 (fr) * 2004-05-18 2005-11-24 University Of Vermont And State Agricultural College Structure cristalline de facteur vai et procede d'identification de modulateurs de facteurs sanguins va
WO2007101106A2 (fr) * 2006-02-23 2007-09-07 The Children's Hospital Of Philadelphia Compositions et méthodes pour moduler une hémostase au moyen de différentes formes de facteur v activé
WO2008067056A2 (fr) * 2006-10-16 2008-06-05 Novelmed Therapeutics, Inc. Procédé d'inhibition de la coagulation avec des anticorps anti-facteur va humains et utilisation de ceux-ci

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910576A (en) * 1994-02-14 1999-06-08 Rijks Universiteit Leiden Method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein
WO2005111075A2 (fr) * 2004-05-18 2005-11-24 University Of Vermont And State Agricultural College Structure cristalline de facteur vai et procede d'identification de modulateurs de facteurs sanguins va
WO2007101106A2 (fr) * 2006-02-23 2007-09-07 The Children's Hospital Of Philadelphia Compositions et méthodes pour moduler une hémostase au moyen de différentes formes de facteur v activé
WO2008067056A2 (fr) * 2006-10-16 2008-06-05 Novelmed Therapeutics, Inc. Procédé d'inhibition de la coagulation avec des anticorps anti-facteur va humains et utilisation de ceux-ci

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANNETTE VON DRYGALSKI ET AL: "Superior in Vivo Hemostatic Properties of an Engineered Factor Va Variant for Hemophilia Mice", vol. 120, no. 21, 1 November 2012 (2012-11-01), XP002722413, ISSN: 0006-4971, Retrieved from the Internet <URL:https://ash.confex.com/ash/2012/webprogram/Paper50002.html> [retrieved on 20150917] *
KALAFATIS M ET AL: "Contribution of the heavy and light chains of factor Va to the interaction with factor Xa", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 33, no. 21, 31 May 1994 (1994-05-31), pages 6538 - 6545, XP002590638, ISSN: 0006-2960 *
KENNETH SEGERS ET AL: "Coagulation factor V and thrombophilia: Background and mechanisms", THROMBOSIS AND HAEMOSTASIS, vol. 98, no. 3, 17 October 2007 (2007-10-17), pages 530 - 42, XP055175994, ISSN: 0340-6245, DOI: 10.1160/TH07-02-0150 *
SCHLACHTERMAN A ET AL: "Factor V Leiden improves in vivo hemostasis in murine hemophilia models", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, vol. 3, no. 12, 1 December 2005 (2005-12-01), pages 2730 - 2737, XP008130621, ISSN: 1538-7933, DOI: 10.1111/J.1538-7836.2005.01639.X *
SUHNG WOOK KIM ET AL: "Identification of Functionally Important Amino Acid Residues within the C2-Domain of Human Factor V Using Alanine-Scanning Mutagenesis +", BIOCHEMISTRY, vol. 39, no. 8, 1 February 2000 (2000-02-01), pages 1951 - 1958, XP055171137, ISSN: 0006-2960, DOI: 10.1021/bi992256r *
W B FOSTER ET AL: "Monoclonal Antibodies Selective for Activated Factor V", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 258, no. 9, 10 March 1983 (1983-03-10), pages 5606 - 5613, XP055177012, Retrieved from the Internet <URL:http://www.jbc.org/content/258/9/5608.full.pdf> [retrieved on 20150316] *

Also Published As

Publication number Publication date
AR101185A1 (es) 2016-11-30
TW201617371A (zh) 2016-05-16
WO2016005564A2 (fr) 2016-01-14

Similar Documents

Publication Publication Date Title
PH12017502180A1 (en) Tau-binding antibodies
WO2015112886A3 (fr) Protéines de liaison et leurs procédés d&#39;utilisation
HK1250990A1 (zh) 凝血因子xi抗体及使用方法
WO2017087901A3 (fr) Anticorps anti-lag3, compositions comprenant des anticorps anti-lag3 et méthodes de production et d&#39;utilisation d&#39;anticorps anti-lag3
WO2016191643A3 (fr) Agents de liaison à tigit et leurs utilisations
EA201791485A1 (ru) Анти-cd47-антитела и их применения
WO2016054598A3 (fr) Anticorps qui se lient à la glycoprotéine du virus ébola et utilisations associés
WO2015197823A3 (fr) Anticorps et fragments de liaison à l&#39;antigène qui se lient spécifiquement à la protéine tau associée aux microtubules
MX2020010530A (es) Anticuerpos humanizados contra cd269 (bcma).
PH12017502207A1 (en) Tau-binding antibodies
EP3176181A4 (fr) Anticorps monoclonal anti-ctla4 ou fragment de celui-ci se liant à l&#39;antigène, composition médicinale et son utilisation
WO2016004389A3 (fr) Protéines de liaison monovalentes
WO2016014974A3 (fr) Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispécifiques, anticorps anti-cd3 activables multispécifiques et procédés d&#39;utilisation de ces anticorps
EP4324518A3 (fr) Molécules d&#39;anticorps anti-tim-3 et leurs utilisations
SG10201909716RA (en) Modified j-chain
HK1202877A1 (en) Anti-cd98 antibodies and methods of use thereof
WO2014163714A3 (fr) Conjugués médicament-anticorps
WO2017019957A3 (fr) Protéines de liaison et leurs procédés d&#39;utilisation
WO2015153997A3 (fr) Anticorps anti-notch 3 et leurs utilisations
WO2016007919A3 (fr) Fragments d&#39;anticorps pour détecter un cancer et méthodes d&#39;utilisation
EP3150632A3 (fr) Anticorps anti-ricine et leurs utilisations
MX2017007747A (es) Anticuerpos para il-17c.
WO2016005564A3 (fr) Anticorps dirigés contre le facteur v activé
WO2016135462A8 (fr) Traitement
WO2016057726A3 (fr) Anticorps humains anti-vegfr-2/kdr

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15736498

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15736498

Country of ref document: EP

Kind code of ref document: A2